



Press Release

## **Valbiotis launches an exclusive commercial benefit for its shareholders: a 20% discount on Valbiotis<sup>PRO</sup>® and Valbiotis<sup>PLUS</sup>® ranges**

**La Rochelle, January 26, 2026** (5:40 PM CEST) – **Valbiotis** (FR0013254851 – ALVAL, PEA/PME eligible), a French laboratory specializing in the design and distribution of scientifically tested dietary supplements to support health at every stage of life, announces its introduction of a promotional offer reserved for its individual shareholders. This initiative aims to strengthen the link between the Company and its shareholders and reward their commitment, while introducing Valbiotis products to those who support the Company's growth.

Starting January 26, 2026, shareholders holding at least 85 Valbiotis shares will be eligible for a 20% discount on all products sold through the Company's e-commerce site.

*"Through this program, we want to thank our shareholders for their trust and loyalty by offering them a rich and distinctive experience. As a company dedicated to preserving health, it feels only natural for us to build this close connection by getting them involved in our world of scientifically tested Valbiotis<sup>PRO</sup>® solutions and our Valbiotis<sup>PLUS</sup>® range, designed to address signs associated with cardiometabolic imbalances and everyday health concerns,"* **says Sébastien Peltier, CEO and Co-Founder** of Valbiotis.

### **Terms and conditions of the commercial benefit reserved for Valbiotis shareholders**

**Discount amount:** 20% applicable to orders placed exclusively on the Valbiotis e-commerce site ([www.valbiotis.com/fr-fr](http://www.valbiotis.com/fr-fr)), with no minimum purchase required.

**Minimum holding:** 85 Valbiotis shares, in registered or bearer form, subject to providing valid proof of share ownership.

**Practical details:** Benefit obtained through Customer Service at [service-client@valbiotis.com](mailto:service-client@valbiotis.com), with each shareholder required to provide: 1) the email address associated with their customer account or, failing that, the email address that will be used when creating their future customer account on the Valbiotis website; and 2) proof of share ownership.

**Duration:** Benefit valid for 12 months from the date of activation by Customer Service.

## About Valbiotis

Valbiotis is a French laboratory specializing in the development and distribution of scientifically tested dietary supplements designed to support health at every stage of life. Through an innovative approach combining scientific excellence, plant expertise and the richness of natural ingredients, Valbiotis offers a new generation of dietary supplements aimed at promoting cardio-metabolic balance and overall well-being, and addressing everyday health concerns such as sleep, fatigue, mood regulation, immunity and vitality. Created at the beginning of 2014 in La Rochelle, France, Valbiotis has forged numerous partnerships with leading academic centers.

Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information on Valbiotis®, please visit: [www.valbiotis.com](http://www.valbiotis.com)

## Contacts

### Corporate Communication / Valbiotis

**Caroline Lamberti**

+ 33 6 77 82 56 88

[caroline.lamberti@valbiotis.com](mailto:caroline.lamberti@valbiotis.com)

### Financial Communication / Seitosei.Actifin

**Marianne Py**

+33 6 85 52 76 93

[marianne.py@seitosei-actifin.com](mailto:marianne.py@seitosei-actifin.com)

### Media Relations/ LJ Com by JIN

**Valentine Martin**

+33 6 32 29 43 82

[v.martin@ljcom.net](mailto:v.martin@ljcom.net)



Name: Valbiotis

ISIN Code: FR0013254851

Ticker Symbol: ALVAL

EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in Valbiotis' Universal Registration Document filed with the Autorité des marchés financiers (AMF) on April 26, 2023 under No. D.23-0347 as well as its Amendment filed with the AMF on December 11, 2023 under No. D. 23-0347.A01, available on the Company website ([www.valbiotis.com](http://www.valbiotis.com)). This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis' shares or financial securities in any country.